A phase 1 clinical trial of ABI-009, an mTOR inhibitor, for patients with severe pulmonary arterial hypertension (PAH) 2018-12-13T18:53:14+00:00

Clinical Trials

September 20, 2018

A phase 1 clinical trial of ABI-009, an mTOR inhibitor, for patients with severe pulmonary arterial hypertension (PAH)

  • Study Sponsor: Aadi Bioscience LLC
  • Institution: Aadi Bioscience LLC
  • Start Date: Thursday, December 10, 2015
  • End Date: Tuesday, December 31, 2019
  • Design: 
    •  Background treatment allowed
    • Open-label
  • Age range (years): 18 to 100
  • Type of PH
    • All PAH (Group 1 PH)
    • IPAH
    • Heritable – APAH
    • CTD – APAH
    • CHD – APAH
  • Study Duration for individual patient: 16 weeks
  • Contact: https://clinicaltrials.gov/ct2/show/NCT02587325